Home About CDC Press Room Funding A-Z Index Centers, Institute & Offices Training & Employment Contact Us
CDC Centers for Disease Control and Prevention Home Page
_  
 
Health & Safety TopicsPublications & ProductsData & StatisticsConferences & Events
 
Program Contents
bullet Programs
Contact Info

English and Spanish
(800) CDC-INFO
(800) 232-4636
TTY: (888) 232-6348
FAX: (770) 488-4760

International Travel
Phone: 1-887-394-8747
Contact CDC-INFO

Keep your kids healthy. cdc.gov/parents
 

Unexplained Deaths & Critical Illnesses

Disease Listing | General Information | Technical Information | Additional Information

Clinical Features Critical illness or death from a potentially infectious cause occurring in previously healthy persons. No etiology identified on initial testing.
Etiologic Agents Multiple. Results of primary and secondary testing provided evidence of presumed etiologies in 28% of cases including disease due to the following pathogens: Streptococcus pneumoniae (15), Influenza A/B viruses (11), Mycoplasma pneumoniae (8), Neisseria meningitidis (7), Group A Streptococcus (5), Enterovirus (5), Chlamydia pneumoniae (4), Adenovirus (3), Legionella spp. (3), Bartonella spp. (3).
Incidence At least 0.5 cases per 100,000 persons 1-49 years of age. Most common clinical syndromes are central nervous system (meningitis, encephalitis) (26%), respiratory (33%), cardiac (16%), sepsis/multiorgan failure (14%), hepatic (4%).
Sequelae Overall, 62% of cases are fatal; of these, 79% had autopsies.
Transmission Varied. Unknown mode of transmission for unexplained cases.
Risk Groups General population.
Surveillance Active population-based surveillance through coroners and medical examiners in four Emerging Infections Program (EIP) sites with total population of 6.7 million 1-39 year olds. Active institution-based surveillance for severe pneumonia is conducted at selected EIP sites. National and international surveillance is passive for clusters of unexplained deaths and illnesses.
Trends Efforts to more readily identify emerging pathogens will depend on both advances in diagnostic tests and modifications in public health surveillance. Bioterrorism preparedness requires the capacity to detect and evaluate cases or clusters of unexplained deaths or critical illnesses.
Challenges Simplify the case-finding methods; improve collaboration between clinicians, pathologists and public health practitioners; enhance the quality of clinical specimens available for testing; systematically evaluate role and utility of new techniques for identifying infectious pathogens.
Opportunities Build an infrastructure to evaluate cases of unexplained infectious disease; respond to clusters of unexplained illness in the United States and abroad; detect emerging pathogens or possible acts of biologic terrorism by challenging the limits of our diagnostic capabilities.
 
 
Date: October 25, 2005
Content source: National Center for Immunization and Respiratory Diseases: Division of Bacterial Diseases
 
    Home   |   Policies and Regulations   |   Disclaimer   |   e-Government   |  FOIA   |  Contact Us  
Safer, Healthier People USA.govDHHS Department of Health
and Human Services
Centers for Disease Control and Prevention,1600 Clifton Rd, Atlanta, GA 30333, U.S.A
English and Spanish: (800) CDC-INFO / (800) 232-4636
TTY: (888) 232-6348 / FAX: (770) 488-4760